Cargando…

The Influence of Treatment with Ledipasvir/Sofosbuvir on Growth Parameters in Children and Adolescents with Chronic Hepatitis C

Background: There are limited data available on the influence of direct-acting antivirals used to treat chronic hepatitis C (CHC) on growth in children. In this study, we aimed to analyze the growth parameters in children treated with ledipasvir/sofosbuvir (LDV/SOF). Methods: We included 38 patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pokorska-Śpiewak, Maria, Dobrzeniecka, Anna, Marczyńska, Magdalena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8950924/ https://www.ncbi.nlm.nih.gov/pubmed/35336881 http://dx.doi.org/10.3390/v14030474

Ejemplares similares

One-Year Outcomes after Ledipasvir/Sofosbuvir Treatment of Chronic Hepatitis C in Teenagers with and without Significant Liver Fibrosis—A Case Series Report
por: Pokorska-Śpiewak, Maria, et al.
Publicado: (2021)

Real-Life Experience with Ledipasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Virus Infection with Genotypes 1 and 4 in Children Aged 12 to 17 Years—Results of the POLAC Project
por: Pokorska-Śpiewak, Maria, et al.
Publicado: (2021)

Efficacy and Safety of the Treatment of Chronic Hepatitis C with Sofosbuvir/Ledipasvir in Children Aged 5 to 10 Years with Comorbidities—A Brief Report
por: Pokorska-Śpiewak, Maria, et al.
Publicado: (2022)

Clinical utility of ledipasvir/sofosbuvir in the treatment of adolescents and children with hepatitis C
por: Yang, Christine Hong Ting, et al.
Publicado: (2018)

HBV and HCV Infection in Children and Adolescents
por: Pokorska-Śpiewak, Maria, et al.
Publicado: (2023)

The influence of hepatitis B and C virus coinfection on liver histopathology in children
por: Pokorska-Śpiewak, Maria, et al.
Publicado: (2014)

Clinical usefulness of new noninvasive serum biomarkers for the assessment of liver fibrosis and steatosis in children with chronic hepatitis C
por: Pokorska-Śpiewak, Maria, et al.
Publicado: (2017)

Novel serum biomarkers modified by the body mass index z-score for the detection of liver fibrosis and steatosis in children with chronic hepatitis C
por: Pokorska-Śpiewak, Maria, et al.
Publicado: (2017)

Subgroup Differences in Response to 8 Weeks of Ledipasvir/Sofosbuvir for Chronic Hepatitis C
por: O'Brien, Thomas R., et al.
Publicado: (2014)

Decreasing racial disparity with the combination of ledipasvir–sofosbuvir for the treatment of chronic hepatitis C
por: Naylor, Paul H, et al.
Publicado: (2017)

Quality of life of Japanese patients with chronic hepatitis C treated with ledipasvir and sofosbuvir
por: Younossi, Zobair M., et al.
Publicado: (2016)

Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany
por: Stahmeyer, Jona T., et al.
Publicado: (2017)

Ledipasvir‐Sofosbuvir for 12 Weeks in Children 3 to <6 Years Old With Chronic Hepatitis C
por: Schwarz, Kathleen B., et al.
Publicado: (2019)

Liver steatosis in children with chronic hepatitis B and C: Prevalence, predictors, and impact on disease progression
por: Pokorska-Śpiewak, Maria, et al.
Publicado: (2017)

Non-Vertical Exposures to HIV, HBV and HCV Infection in Children and Adolescents—Risk of Infection, Standards of Care and Postexposure Prophylaxis
por: Tomasik, Anna, et al.
Publicado: (2021)

Effectiveness of sofosbuvir/ledipasvir in hepatitis C virus infection in children and adolescents with malignancy: tertiary center experience
por: Ibraheem, Mohammad Fadhil, et al.
Publicado: (2022)

Reply: Subgroup Differences in Response to 8 Weeks of Ledipasvir/Sofosbuvir for Chronic Hepatitis C
por: O’Brien, Thomas R., et al.
Publicado: (2015)

Patient-reported Outcomes in Asian Patients With Chronic Hepatitis C Treated With Ledipasvir and Sofosbuvir
por: Younossi, Zobair M., et al.
Publicado: (2016)

Ledipasvir/Sofosbuvir Is Effective as Sole Treatment of Porphyria Cutanea Tarda with Chronic Hepatitis C
por: Bonkovsky, Herbert L., et al.
Publicado: (2023)

Treatment with ledipasvir-sofosbuvir for hepatitis C resulting in improvement of lichen planus
por: Ansari, Umer, et al.
Publicado: (2017)

Non-invasive evaluation of the liver disease severity in children with chronic viral hepatitis using FibroTest and ActiTest – comparison with histopathological assessment
por: Pokorska-Śpiewak, Maria, et al.
Publicado: (2017)

Management of hepatitis C in children and adolescents during COVID-19 pandemic
por: Pokorska-Śpiewak, Maria, et al.
Publicado: (2020)

Analysis of Subgroup Differences in the ION-3 Trial of Ledipasvir-Sofosbuvir in Chronic Hepatitis C Infection
por: Kowdley, Kris V., et al.
Publicado: (2015)

Acute Kidney Injury in Patients Undergoing Chronic Hepatitis C Virus Treatment With Ledipasvir/Sofosbuvir
por: Brown, Patrick R., et al.
Publicado: (2018)

Real-World Efficacy and Safety of an 8-Week Glecaprevir/Pibrentasvir Regimen in Children and Adolescents with Chronic Hepatitis C—Results of a Multicenter EpiTer-2 Study
por: Pawlowska, Malgorzata, et al.
Publicado: (2023)

Autoimmune Hepatitis During Ledipasvir/Sofosbuvir Treatment of Hepatitis C: A Case Report
por: Covini, Giovanni, et al.
Publicado: (2018)

Role of ledipasvir/sofosbuvir combination for genotype 1 hepatitis C virus infection
por: Sundaram, Vinay, et al.
Publicado: (2016)

Ledipasvir/Sofosbuvir Effectively Treats Hepatitis C Virus Infections in an Underserved Population
por: Stewart, Rachel A., et al.
Publicado: (2018)

Effectiveness of Ledipasvir/Sofosbuvir with/without Ribavarin in Liver Transplant Recipients with Hepatitis C
por: Saab, Sammy, et al.
Publicado: (2017)

Ledipasvir/Sofosbuvir Eradicates Hepatitis C in an Immunodeficient STAT3-GOF Patient
por: Thalhammer, Julian, et al.
Publicado: (2021)

Safety and Efficacy of Ledipasvir/Sofosbuvir in the Treatment of Chronic Hepatitis C Virus Infection in Treatment-Naïve Children without and with Comorbidities
por: AbouBakr, Othman, et al.
Publicado: (2022)

Combination ledipasvir-sofosbuvir for the treatment of chronic hepatitis C virus infection: a review and clinical perspective
por: Nkuize, Marcel, et al.
Publicado: (2016)

Severe chronic atopic dermatitis improvement after hepatitis C virus elimination with sofosbuvir/ledipasvir treatment
por: Szymanek-Pasternak, Anna, et al.
Publicado: (2022)

Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany
por: Buggisch, Peter, et al.
Publicado: (2019)

Miliary tuberculosis infection during hepatitis C treatment with sofosbuvir and ledipasvir plus ribavirin
por: Ballester-Ferré, Maria Pilar, et al.
Publicado: (2017)

Ledipasvir and Sofosbuvir in the Treatment of Early Hepatitis C Virus Infection in HIV-Infected Men
por: Palaniswami, Paari M, et al.
Publicado: (2018)

Effectiveness of 12 week ledipasvir/sofosbuvir and predictors of treatment failure in patients with hepatitis C
por: del Rio-Valencia, Juan Carlos, et al.
Publicado: (2019)

Ledipasvir/Sofosbuvir for Patients Coinfected With Chronic Hepatitis C and Hepatitis B in Taiwan: Follow-up at 108 Weeks Posttreatment
por: Liu, Chun Jen, et al.
Publicado: (2021)

Liver Fibrosis Is Associated With Corrected QT Prolongation During Ledipasvir/Sofosbuvir Treatment for Patients With Chronic Hepatitis C
por: Tahata, Yuki, et al.
Publicado: (2018)

Treatment efficacy of ledipasvir/sofosbuvir for 8 weeks in non-cirrhotic chronic hepatitis C genotype 4 patients
por: Babatin, Mohammed A., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_3ukghf28c7ur6ul6usp2pr961j